title: An alternative combination therapy for type 2 diabetes?
authors.affiliation: Center for Diabetes Research, Department of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup 2900, Denmark. Electronic address: s.ostoft@dadlnet.dk.
authors.forename: Signe H
authors.initials: SH
authors.lastname: Østoft
authors.affiliation: Center for Diabetes Research, Department of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup 2900, Denmark; Department of Clinical Pharmacology, Bispebjerg Hospital, University of Copenhagen, Hellerup 2900, Denmark.
authors.forename: Mikkel
authors.initials: M
authors.lastname: Christensen
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D004763:Glucagon-Like Peptides / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D007141:Immunoglobulin Fc Fragments / Q000008:administration & dosage*; D000069036:Insulin Glargine; D061268:Insulin Lispro / Q000008:administration & dosage*; D049528:Insulin, Long-Acting / Q000008:administration & dosage*; D008297:Male; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*
chemical_list: D007004:Hypoglycemic Agents; D007141:Immunoglobulin Fc Fragments; D061268:Insulin Lispro; D049528:Insulin, Long-Acting; D011993:Recombinant Fusion Proteins; D000069036:Insulin Glargine; D004763:Glucagon-Like Peptides; C555680:dulaglutide